No I Did not Write this Seeking Alpha Article - you can tell by the Inaccurate Cash Discussion. REGAL STUDY RESULTS DUE ANY DAY ARE A MAJOR POTENTIAL UPSIDE CATALYST
Clarifying on Cash: SLS Has +/-$100M with a $6.2M-$6.5M Q4 Burn.
Additionally $90M in Warrant Cash incoming, along with $200M for Rare Priority Review Voucher - SLS Fully Cashed Up with Nearly $400M / and tiny Minuscule Burn.
- ANY DAY NOW.
All SLS investors are guaranteed massive ROI, when the Phase 3 Registrational Results are Announced.
- The positive P3 will give Gps the FDA green light to treat 12,000 AML Cr2/3 Patients and 40,000+CR1 patients Each Year - and there are 100,000 Currently in Remission, who'll be eligible and benefit Immediately - $28B TAM
+$28B TAM Right out of the Gate is worth $40B + to Big Pharma / $180 Per Share.
--- > All REGAL Phase 3 Patients have been enrolled at Least 24 months ago.
- There are No Trials w Published Data for AML Cr2 Patients, surviving much past 12 month, very rare past 18/20 and Literally NIL survival, absent transplant at 24+ months = +/- 60 Events just Control While We AWAIT 80.
Gps P2 Statistically Significant MOS was Less than 24 months / 21 months.
Posted Mar 8, 2026, 8:05 PM UTC